New CAR T-cell therapy receives FDA approval for human trials
Phase 1 trial evaluating the safety and clinical activity of CYAD-02 is planned for early 2020 and will involve a preconditioning chemotherapy in patients with relapse/refractory acute myeloid leukemia or myelodysplastic syndromes (Credit: Wikimedia Commons)